Frankfurt/Main, May 9, 2007 — Shearman & Sterling represented MorphoSys AG in connection with the placement of 652,188 shares with institutional investors in Europe and North-America. The gross proceeds from the capital increase amounted to €32.6 million.

Société Générale and WestLB AG acted as joint lead managers in this transaction, joined by Janney Montgomery Scott acting as selling agent in the USA. The new shares are traded at the Frankfurt Stock Exchange as of May 9, 2007. The proceeds from the capital increase will be used to further expand the research antibody segment and to increase the flexibility for future growth of the MorphoSys-Group.